The approval of the combination therapy of Enkofinib capsules in China for second-line treatment of metastatic colorectal cancer

Recently, the Pfizer Group announced that its products Encorafanib capsules and Cetuximab have received approval from the China National Medical Products Administration for their combination therapy for adult patients with BRAF V600E-mutant metastatic colorectal cancer who have previously received systemic treatment.